NCT07155369View on ClinicalTrials.gov

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

NAActive, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2028

Conditions
Systemic Lupus ErythematosusSystemic Sclerosis
Interventions
BIOLOGICAL

UCAR-T cells

UCAR-T cells will be administered intravenously as per the schedule specified in the protocol.

DRUG

Cyclophosphamide

Cyclophosphamide will be administered intravenously.

DRUG

Fludarabine

Fludarabine will be administered intravenously.

Trial Locations (1)

Unknown

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
collaborator

Shanghai Xiniao Biotech Co., Ltd.

INDUSTRY

lead

The Affiliated Hospital of Xuzhou Medical University

OTHER

NCT07155369 - UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases | Biotech Hunter | Biotech Hunter